GALECTIN THERAPEUTICS INC - COM NEW (GALT)

Q1 2024 13F Holders as of 31 Mar 2024

Type / Class
Equity / COM NEW
Total 13F shares
7,591,787
Share change
+416,010
Total reported value
$18,144,362
Put/Call ratio
0%
Price per share
$2.39
Number of holders
58
Value change
+$1,189,286
Number of buys
20
Number of sells
19

Institutional Holders of GALECTIN THERAPEUTICS INC - COM NEW (GALT) as of Q1 2024

As of 31 Mar 2024, GALECTIN THERAPEUTICS INC - COM NEW (GALT) was held by 58 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 7,591,787 shares. The largest 10 holders included VANGUARD GROUP INC, OSAIC HOLDINGS, INC., BlackRock Inc., GEODE CAPITAL MANAGEMENT, LLC, Geneos Wealth Management Inc., Wealthspire Advisors, LLC, SUSQUEHANNA INTERNATIONAL GROUP, LLP, Atria Wealth Solutions, Inc., MORGAN STANLEY, and STATE STREET CORP. This page lists 57 institutional shareholders reporting positions in this security for the Q1 2024 filing period.
Investor Option Weight % Change % Value $ * Price Shares Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.